Jason Ford

UK government invests in R&D for personalised medicine

News

The Technology Strategy Board (TSB) and the Medical Research Council (MRC) are to invest more than £3.7m in research projects designed to place the UK at the forefront of developments in personalised medicine.

According to a statement, the investment is the first to be made through the TSB-managed Stratified Medicine Innovation Platform (SMIP), an initiative that will oversee an investment of more than £50m of government funding over five years in R&D, in areas such as tumour profiling, to improve cancer care, and developing biomarkers for more effective drugs.

The seven projects will be lead by AstraZeneca UK, GlaxoSmithKline, Ig Innovations, Janssen UK and Randox Laboratories.

Including contributions from the project partners, the total value of the research and development will be more than £7m.

Iain Gray, TSB chief executive, said: ‘Here in the UK we have many of the strengths needed to accelerate the innovation of stratified — or personalised — medicines and to become a world leader in developing medicines aimed at smaller sub-groups of patients.

‘These investments are the first in a programme that is bringing scientific research, businesses and policy makers together to develop the personalised, targeted drugs and treatments of the future.’

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox

Register
Or continue by

Signing in with your registered email address